FMR LLC - 30 Jan 2025 Form 3 Insider Report for Metsera, Inc. (MTSR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
30 Jan 2025, 18:28:05 UTC
Prior SEC filing
10 Jan 2025
Next SEC filing
05 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson

Key filing fact

FMR LLC filed Form 3 for Metsera, Inc. (MTSR) on 30 Jan 2025.

Key facts

  • This page summarizes FMR LLC's Form 3 filing for Metsera, Inc. (MTSR).
  • 0 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 30 Jan 2025, 18:28.

Change

  • Previous filing in this sequence was filed on 10 Jan 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTSR holding Derivative

Series Seed Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
30 Jan 2025
Ownership
F-Prime Capital Partners Life Sciences Fund VIII LP
Underlying class
Common Stock
Underlying amount
1,418,606
Exercise price
Footnotes
F1
MTSR holding Derivative

Series A Preferred Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
30 Jan 2025
Ownership
F-Prime Capital Partners Life Sciences Fund VIII LP
Underlying class
Common Stock
Underlying amount
3,120,934
Exercise price
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Series Seed Preferred Stock and Series A Preferred Stock are convertible on a 1-for-1 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.

SEC remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VIII LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VIII LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .